These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25406295)

  • 1. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia.
    Espedido BA; Jensen SO; van Hal SJ
    J Antimicrob Chemother; 2015 Mar; 70(3):797-801. PubMed ID: 25406295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
    Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
    Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
    Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
    Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
    Barber KE; Rybak MJ; Sakoulas G
    J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.
    Ho TT; Cadena J; Childs LM; Gonzalez-Velez M; Lewis JS
    J Antimicrob Chemother; 2012 May; 67(5):1267-70. PubMed ID: 22311935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
    Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
    J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Davis KP; McDermott LA; Snydman DR; Aldridge BB
    Microbiol Spectr; 2024 Aug; 12(8):e0097624. PubMed ID: 38916355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
    García P; Moscoso M; Fernández MC; Fuentes-Valverde V; Pérez A; Bou G
    Int J Antimicrob Agents; 2023 Jul; 62(1):106836. PubMed ID: 37150362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
    Lodise TP; Drusano GL; Lazariu V; El-Fawal N; Evans A; Graffunder E; Stellrecht K; Mendes RE; Jones RN; Cosler L; McNutt LA
    J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS; Flamm RK; Farrell DJ; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS; Jones RN; Rossi KL; Rybak MJ
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.